Nevertheless, according to the NCI‐9742 and POLARIS‐02 clinical trials, less than half of patients with PD‐L1+‐expressing NPC respond to anti‐PD‐1 ICIs.30, 31. This evidence concerns the gene CD274 and nasopharyngeal carcinoma.